NEW YORK (GenomeWeb News) – Agendia has filed for an initial public offering to sell shares on the NYSE Euronext in Amsterdam.
The Dutch molecular diagnostics firm plans to sell up to 4,587,156 newly issued ordinary shares at a price of between €16.35 to €19.15 per share. At the mid-point of that range, it would raise around €81.4 million ($119 million), before an over-allotment option of up to 688,073 newly issued ordinary shares.
Agendia expects to begin trading on the NYSE Euronext in Amsterdam on June 21, under the symbol "AGDX".
The firm will use the proceeds partly to expand its sales and marketing efforts in the US. Agendia sells the MammaPrint breast cancer recurrence assay, the first in vitro diagnostic multivariate index assay device approved by the US Food and Drug Administration in early 2007.